200,574 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Purchased by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. bought a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 200,574 shares of the company’s stock, valued at approximately $5,550,000. Hillsdale Investment Management Inc. owned about 0.27% of Kiniksa Pharmaceuticals International as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Kiniksa Pharmaceuticals International by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock worth $74,606,000 after purchasing an additional 151,604 shares in the last quarter. Acadian Asset Management LLC lifted its position in Kiniksa Pharmaceuticals International by 22.6% during the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock valued at $35,067,000 after purchasing an additional 233,668 shares during the last quarter. Millennium Management LLC grew its stake in Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after buying an additional 67,452 shares in the last quarter. Nuveen LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth $16,992,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Kiniksa Pharmaceuticals International by 56.0% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 623,689 shares of the company’s stock valued at $17,257,000 after buying an additional 223,946 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Trading Up 0.2%

Shares of NASDAQ:KNSA opened at $41.58 on Friday. The stock has a market capitalization of $3.15 billion, a P/E ratio of 92.40 and a beta of 0.16. The stock’s 50-day moving average price is $38.43 and its 200-day moving average price is $32.86. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $42.93.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same period last year, the firm posted ($0.18) EPS. The company’s revenue was up 61.2% on a year-over-year basis. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Analysts Set New Price Targets

KNSA has been the subject of several research reports. TD Cowen initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a “buy” rating and a $60.00 target price for the company. Citigroup lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, July 29th. Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. Finally, The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $52.00.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 50,490 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $38.87, for a total transaction of $1,962,546.30. Following the completion of the sale, the chief accounting officer owned 27,046 shares of the company’s stock, valued at $1,051,278.02. This represents a 65.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Mark Ragosa sold 19,900 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $40.94, for a total transaction of $814,706.00. Following the completion of the sale, the chief financial officer directly owned 31,086 shares in the company, valued at approximately $1,272,660.84. This trade represents a 39.03% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 622,513 shares of company stock valued at $23,607,641. Insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.